Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

TCTMD’s Top 10 Most Popular Stories for July 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

July 31, 2025

Heart Disease Treatment Costs $100 Billion per Year in the US

News Daily News

Heart Disease Treatment Costs $100 Billion per Year in the US

July 30, 2025

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

July 16, 2025

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

AHA Offers Help for Clinicians Weighing the Results of DTC Genetic Tests

News Daily News

AHA Offers Help for Clinicians Weighing the Results of DTC Genetic Tests

Yael L. Maxwell

March 18, 2025

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Use of Secondary CVD Prevention Meds Still Meager Worldwide

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

February 03, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.